Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Illustration: Sarah Grillo/Axios
Moderna has moved incredibly quickly to begin testing a potential vaccine for the new coronavirus in U.S. patients. The biotech company went from taking the genetic sequence of the new coronavirus to manufacturing its first batch of vials in less than a month.
Reality check: Best-case scenario, a vaccine could be ready for production by next year — but that's assuming the drug proves to be both safe and effective, which is completely unknown right now.
What they're saying: My colleague Dan Primack and I spoke with Moderna CEO Stéphane Bancel to understand the timing of this very fluid situation.
- After this phase 1 trial and a potential phase 2 trial over the summer, Bancel believes the vaccine can begin a phase 3 trial by this fall.
- A phase 3 trial would enroll at least 3,000 people, and if data shows the vaccine is safe and effective for that sample, the FDA could approve it.
- Anthony Fauci of the NIH has said it's a possibility there could be a novel coronavirus vaccine in 2021, "and I would agree with that," Bancel said.
Yes, but: There's no data yet. It's a scientific feat to get to this stage so quickly, but that will matter a lot less if the vaccine doesn't work well or if people suffer serious side effects.
- "We cannot make any mistakes on safety," Bancel said.
The intrigue: Moderna, which uses a complex gene-based technology that changes how cells function, has a lot of experience researching vaccines — it has done some animal testing on a vaccine for a related coronavirus, MERS.
- But none of Moderna's vaccines have led to federal approvals yet.
The bottom line: The global desire to find something to prevent another COVID-19 pandemic should not kick aside the need for scientific evidence.